[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sleep-deprivation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sleep-deprivation":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,31,0,25,[9,49,84,113,139,167,207,235,269,292,317,350,369,395,414,440,471,503,524,545,618,644,674,702,729],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100521924","ketone-conferred-resiliency-against-sleep-restriction-with-nutritional-intervention-100521924",false,"NCT06075914","Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.","Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention (STAK - Sleep + Feed)","Inclusion Criteria:\n\n* Healthy, 18-40 years old.\n* BMI: 20-35 kg\u002Fm2\n* Sleep at least 7h per night.\n* Willing to participate in \\~9-weeks of testing and provided food.\n* Willing to adhere to all study procedures.\n\nExclusion Criteria:\n\n* \\\u003C18 or \\>40 years of age\n* \\>35 body mass index (BMI).\n* Diagnosed sleeping disorders (i.e., sleep apnea, insomnia).\n* Gastrointestinal disorders or food allergies that would interfere with consuming the study supplements.\n* Drink alcohol in excess of 3 drinks\u002Fday or 14 drinks\u002Fweek\n* Have any conditions or contraindications to blood draws.\n* Have been diagnosed with diabetes, liver, kidney, or other metabolic or endocrine dysfunction, or use diabetic medications other than metformin\n* Currently consume a low carbohydrate or ketogenic diet or have done so in the last 3 months\n* Have experienced weight loss of \\>10% of your body weight within the last 6 months\n* Are pregnant, lactating, or planning on becoming pregnant during the study\n* Have any major psychiatric disorders (e.g., schizophrenia, bipolar disorder)",true,"ALL","18 Years","40 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","Sleep deprivation is a major problem in military populations. Some major consequences of sleep loss are inability to concentrate, poor work efficiency, and increase in errors during daily tasks. Ketogenic supplementation is speculated to alleviate some sleep deprivation issues via action of ketones. Ketones are small molecules that appear in the blood when following a ketogenic diet or consuming ketone supplements. The goal of this project is to find out if diet and\u002For ketones can improve sleep deprivation detriments over 5 days of sleep restriction (-50% from habitual sleep).",[29,30],"Sleep Deprivation","Nutritional Intervention",[32,33,34,35],"Ketogenic Diet","Mediterranean Diet","Ketone Esters","Placebo","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2023-05-01",{"date":44,"type":23},"2027-02",{"name":46,"class":47},"Ohio State University","OTHER",1,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":48},"100626690","mind-after-midnight-100626690","NCT07438912","Mind After Midnight","The Mind After Midnight: Mechanistic Examination of Nocturnal Wakefulness as a Suicide Risk Factor","MaM","Inclusion Criteria\n\n* Age 18-55 years\n* History of suicidal ideation within the past 6 months\n* Habitual bedtime between 9:00 PM and 1:00 AM\n* Habitual wake time between 6:00 AM and 9:00 AM\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Current suicidal intent requiring immediate clinical intervention\n* Diagnosis of a primary sleep disorder (e.g., untreated obstructive sleep apnea, narcolepsy)\n* Bipolar disorder or psychotic disorder\n* Substance use disorder within the past 3 months\n* Use of medications that significantly affect sleep or circadian rhythms\n* Night shift work or transmeridian travel within the past month\n* Medical or neurological condition that would interfere with participation\n* Pregnancy","55 Years",{"count":59,"type":23},90,[26],"This study examines whether wakefulness during the biological night (2:00-4:00 AM) is associated with increased negative mood, impaired decision-making, and suicidal thoughts. Adults with a history of suicidal ideation in the past six months will complete laboratory and home-based assessments under varying levels of sleep pressure. Participants will be evaluated during late-night wakefulness and under conditions of both higher and lower sleep pressure. The goal of the study is to better understand the biological and behavioral mechanisms that may contribute to elevated suicide risk during nocturnal wakefulness.",[63,64,29,65],"Suicidal Ideation","Circadian Rhythm Disorders","Sleep Wake Disorders",[67,68,69,70,71,72,73,74],"Nocturnal Wakefulness","Suicide Risk","Circadian Misalignment","Impulsivity","Mood Regulation","Biological Night","Sleep Pressure","Decision-Making","2026-05-19",{"date":77,"type":40},"2026-05-22",{"date":79,"type":40},"2026-03-06",{"date":81,"type":23},"2029-08-31",{"name":83,"class":47},"University of Arizona",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100481616","reestablishing-sleep-and-circadian-alignment-in-medical-intensive-care-unit-micu-patients-via-a-mechanistic-rct-of-an-sleep-chronobundle-100481616","NCT05551325","Reestablishing Sleep and Circadian Alignment in Medical Intensive Care Unit (MICU) Patients Via a Mechanistic RCT of an Sleep Chronobundle","Reestablishing Sleep and Circadian Alignment in Medically Critically Ill Patients Via a Mechanistic Randomized Controlled Trial (RCT) of an Intensive Care Unit (ICU) Sleep Chronobundle","ReAlign-ICU","Inclusion:\n\n* Critically ill patients admitted to the MICU who require mechanical ventilation, noninvasive ventilation, high flow nasal cannula, or vasopressor support and who remain on qualifying support as of 09:00 on study randomization day. Randomization will occur on the second or third calendar day following MICU admission. MICU admission must have occurred within 24 hours of hospital admission.\n* Age greater than or equal to 18 years old.\n\nExclusion:\n\n* Not expected to remain in the MICU for at least 48 hours post-randomization.\n* Imminently dying or with a hospice status.\n* At significant risk for pre-existing circadian abnormalities including: (1) severe chronic brain injury (injury greater than 30 days ago resulting in the inability to live independently); (2) acute brain injury of any severity that is reasonably expected to impact the central circadian clock (e.g., cardiac arrest); (3) documented circadian disorder (\\\u003C1% population) or blind\u002Fdisease of the optic nerve; (4) current or recent (last 1 year) shiftwork; and (5) homelessness, incarceration, or institutionalization.\n* At elevated risk of aspiration due to structural or functional abnormality of the gastrointestinal tract OR fed via enteral nutrition (e.g., \"tube feeds\") prior to ICU admission.\n* Admitted to the ICU for treatment of diabetic ketoacidosis or hyperosmolar state; this diagnosis will be established via review of the medical record for a description of diabetes in the past medical history or the presence of diabetes medication on the confirmed home medication list AND hyperglycemia attributed to diabetic ketoacidosis or diabetic hyperosmolar state by the admitting care team in their written assessment of the patient.\n* Having a history of hypoglycemia without documented full neurological recovery; this diagnosis will be established via review of the patient's past medical history in the medical record;\n* Having a history suggesting an abnormally high risk of suffering hypoglycemia (e.g., known insulin secreting tumor, history of unexplained or recurrent hypoglycemia or fulminant hepatic failure); this diagnosis will be established via review of the patient's past medical history in the medical record.\n* Admitted due to complications of a suicide attempt.\n* Admitted due to an acute drug overdose or active alcohol withdrawal.\n* Positive for SARS-CoV.\n\nUrine 6-sulfatoxymelatonin measures will be considered for all patients who make sufficient urine and have an appropriate bladder catheter in place during the indicated time points. However, we will exclude patients from urine measures if they have a history or positive test for any known disease or illness that would categorize biological samples as BSL3 or higher. This includes HIV, West Nile virus, Monkeypox, and Mycobacterium tuberculosis (TB).\n\nNote: Patients who leave the MICU within 24 hours of randomization are excluded from further study activities. Patients who leave the MICU between 24 and 48 hours post-randomization continue all study activities but will not be included in the primary analysis. Patients who remain in the MICU for at least 48 hours post-randomization will continue all study activities and be included in the primary analysis.",{"count":93,"type":23},160,[26],"More than 5 million patients are admitted to the intensive care unit every year in the United States; most of these patients experience profound sleep and circadian disruption. Promotion of circadian alignment (i.e., alignment of the body's clocks) would make it possible to strategically schedule behaviors such as sleep and eating at normal body clock times, which is predicted to improve sleep quality and metabolic function. This project will test the ability of a sleep chronobundle (i.e., sleep promotion and circadian treatment bundle) to normalize circadian alignment and subsequently test if this realignment also improves sleep and metabolism.",[97,29,98],"Critical Illness","Circadian Rhythm Sleep Disorder, Unspecified",[100,101,102],"critical illness","sleep deficiency","circadian misalignment","2026-05-18",{"date":105,"type":40},"2026-05-20",{"date":107,"type":40},"2024-05-13",{"date":109,"type":23},"2029-06-29",{"name":111,"class":47},"Yale University",2,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":48},"100568309","effects-of-partial-sleep-deprivation-on-cardiac-output-during-cycling-100568309","NCT06679543","Effects of Partial Sleep Deprivation on Cardiac Output During Cycling","Inclusion Criteria:\n\n* Free of known cardiovascular or metabolic diseases or sleep disorders\n* No history of smoking (within the past 3 months)\n* Able to engage in physical activity assessed through the physical activity readiness questionnaire (PAR-Q+)\n* No prescription of chronic medications other than oral contraceptives\n* Able to abide by sleep protocols for all visits\n* Individuals who are not allergic to ultrasound gel\n* Individuals who are not pregnant\n\nExclusion Criteria:\n\n* Individuals diagnosed with cardiovascular or metabolic disease or sleep disorders\n* Has a history of smoking (within the past 3 months)\n* Not ready to engage in physical activity as assessed by the PAR-Q+\n* Individuals prescribed chronic medications other than oral contraceptives\n* Unable to abide by sleep protocols for any testing visit\n* Allergic to ultrasound gel\n* Pregnancy","50 Years",{"count":121,"type":23},30,[26],"The goal of this clinical trial is to determine if attenuations in cardiac output drive the blunted blood pressure response during cycling exercise following a night of partial sleep deprivation in young healthy adults (%50 females). The secondary outcome is to assess sex differences. The main questions it aims to answer are:\n\n* Do reductions in plasma volume drive reductions in cardiac output and therefore blood pressure during exercise following a night of partial sleep deprivation?\n* Do sex differences exist?\n\nParticipants will:\n\n* Visit the lab after a night of normal sleep and a night of partial sleep deprivation.\n* Keep a daily diary of their sleep and food\u002Fbeverage intake.\n* Perform maximal and submaximal exercise on a cycle ergometer.",[29],[126,127,128,129],"exercise blood pressure","cardiac output","plasma volume","sleep deprivation","2026-04-27",{"date":132,"type":40},"2026-04-28",{"date":134,"type":40},"2025-01-02",{"date":136,"type":23},"2026-12",{"name":138,"class":47},"University of Guelph",{"id":140,"slug":141,"hasResults":12,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":48},"100469516","the-effect-of-sleep-loss-on-emotion-regulation-100469516","NCT05393830","The Effect of Sleep Loss on Emotion Regulation","The Impact of Insufficient Sleep and Insomnia Disorder on Behavioral and Neural Markers of Emotion Regulation","Inclusion Criteria:\n\n* willing and able to follow the protocol\n* willing and able to meet inclusion criteria for fMRI scanning\n* willing to refrain from alcohol and recreational drugs for the duration of the protocol\n* normal or corrected to normal vision is required\n\nExclusion Criteria:\n\n* left-handedness or ambidexterity\n* the use of any drugs that could affect either sleep or cognitive functioning (e.g., prescription sleeping pills or antidepressants)",{"count":59,"type":23},[26],"The study is designed to investigate the impact of three nights of sleep restricted to 4 hours per night, on the processing and regulation of emotional information compared to Insomnia Disorder and control. The investigators will address and attempt to answer two questions.\n\n(i) How do three nights of reduced sleep or a diagnosis of Insomnia Disorder affect the processing and regulation of emotional information compared to typical, undisturbed sleep? (ii) What overlapping and distinct neural mechanisms are engaged and associated with behavioral effects when attempting to process and regulate emotions in a sleep restricted state or with a clinical diagnosis of Insomnia Disorder? This study will investigate sleep's role in emotion processing and regulation. The findings will help further understanding of the role of sleep in healthy emotional functioning.",[150,151,29],"Sleep","Insomnia",[153,154,155,150,156,157],"Emotion","Sleep Restriction","Insomnia Disorder","Emotion Regulation","functional Magnetic Resonance Imaging (fMRI)","2026-04-09",{"date":160,"type":40},"2026-04-14",{"date":162,"type":40},"2023-05-11",{"date":164,"type":23},"2027-07-31",{"name":166,"class":47},"Beth Israel Deaconess Medical Center",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":17,"sex":18,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":185,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":48},"100631047","the-acute-effects-of-onnit-alpha-brain-on-cognition-and-mood-states-100631047","NCT07495592","The Acute Effects of Onnit Alpha Brain on Cognition and Mood States","The Acute Effects of Onnit Alpha Brain on Cognition and Mood States: A Randomized, Crossover, Double Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Healthy males and females aged 20-59\n* Free of chronic diseases.\n* Able to read and write in English\n* Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period\n* Willingness to meet all study requirements and restrictions. Including willing to arrive in lab in a sleep deprived state (\\\u003C or =5 hours), willing to avoid alcohol consumption 72 hours prior to testing days, and willing to avoid caffeine within 12 hours prior to testing days.\n\nExclusion Criteria:\n\n* Habitual high caffeine consumers (\\> 400 mg\u002Fday) assessed through caffeine assessment tool (Caffeine Consumption Questionnaire, CCQ)\n* Unwilling to wear sleep monitor at night\n* Known diagnosis of any cognitive impairment, cardiovascular, metabolic, endocrine, or renal disease\n* Has fever, or cold like symptoms\n* History of anxiety disorders\n* History of sleep disorders (i.e., insomnia), and habitually short sleepers (\\\u003C5 hours of sleep nightly)\n* History or current malignancy\n* Previous gastrointestinal surgery within the past 12 months\n* No alcohol consumption 72 hours prior to the start of the study\u002Fconsumption of the study product and during the testing days\n* No caffeine consumption within 12 hours prior to the start of the study and during the testing days\n* Sleep medicines, melatonin, or marijuana within 1 week of the start of the study\n* Regular smoker\n* Regular drinker (\\>14 drinks per week)\n* Current use (within the past 4 weeks) of dietary supplements or prescription medicines that may enhance cognitive performance (including, but not limited to L-Theanine, Cat's claw bark extract, Alpha GPC, Toothed clubmoss extract (Huperzine A), Bacopa, Phosphatidylserine, Paraxanthine, Pterostilbene, and Sceletium tortuosum).\n* Current use of prescription medications that may influence cognition (hormone therapies, peptides, etc.)\n* Travel involving time zone change, shift work, or other life events that alter sleep schedule \\>3 hours from the norm one week before the start of the study\n* Any subject with a condition deemed by the investigator or sponsor to potentially interfere with study participation\n* Women who have been pregnant within the past 6-months, are breastfeeding, lactating, or presently planning to become pregnant during the duration of the study","20 Years","59 Years",{"count":177,"type":23},34,[26],"The purpose of this randomized, double-blind, placebo-controlled crossover study is to evaluate the efficacy of the acute effects of an investigational supplement (Alpha Brain or Alpha Brain 2.0) on improving cognitive performance, vigilance, and subjective mood in healthy adults compared to placebo during a period of acute sleep deprivation under conditions of controlled sleep deprivation.",[181,182,29,183,184],"Cognitive","Mood and Cognitive Performance","Executive Function (Cognition)","Fatigue",[186,187,188,189,190,191,192,193,194,195],"Alpha Brain","Dietary Supplement","Reaction Time","Attention","Vigilance","Mood States","Psychomotor Vigilance Test","Stroop Test","alertness","Executive Function","NOT_YET_RECRUITING","2026-03-30",{"date":199,"type":40},"2026-04-03",{"date":201,"type":23},"2026-04-16",{"date":203,"type":23},"2026-08-15",{"name":205,"class":206},"Applied Science & Performance Institute","INDUSTRY",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":24,"phases":217,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":48},"100521484","cardiovascular-risk-and-circadian-misalignment-in-short-sleepers---role-of-extended-eating-period-100521484","NCT06070194","Cardiovascular Risk and Circadian Misalignment in Short Sleepers - Role of Extended Eating Period","CRISP","Inclusion Criteria:\n\n* Age: 18-45 years\n* BMI: 25-35 kg\u002Fm2\n* Habitual sleep duration: ≤6.5 h\u002Fnight\n* Habitual eating period: \\>14h\u002Fday\n* Absence of chronic health conditions including hypertension (defined as systolic clinical BP of \\>140 or diastolic BP of \\>90 mmHg or use of BP lowering drugs), dyslipidemia (defined as LDL \\>190mg\u002FdL or Triglycerides \\>400 mg\u002FdL or use of lipid lowering medications), diabetes (defined as fasting glucose \\>126 mg\u002FdL and \u002For HbA1C \\>6.5%, or use of glucose lowering medication), and cardiovascular disease. However, individuals with prehypertension, and\u002For prediabetes will be allowed to participate.\n* Individuals with seasonal allergies will also be included.\n* Women of child-bearing age will be allowed to participate if they agree to use acceptable birth control during the study period.\n* Must be able to provide written informed consent.\n* Ability to follow the prescribed eating duration and maintain habitual diet, sleep and physical activity.\n* Use of certain mediations will be allowed including birth control, second generation antihistamines, antacids, acne-related ointments etc.\n\nExclusion Criteria:\n\n* Irregular sleep habits \u002F night shift \u002F rotating shift work in past 1 month.\n* Frequent travel related jet lag.\n* Pregnant\u002F breast-feeding\u002F history of irregular menstrual cycles.\n* Sleep disorders such as insomnia (defined as Insomnia Severity Index score ≥15), and sleep apnea (overnight oximetry defined oxygen desaturation index of \\>10 events\u002Fh of sleep).\n* Presence of excessive daytime sleepiness (defined as Epworth Sleepiness Scale score \\>10).\n* Recent changes in body weight (≥5%) within 3 months.\n* Uncontrolled depression and \u002For anxiety, history of psychosis or bipolar disorder.\n* Uncontrolled depression and\u002For depression is defined as PHQ-9 score of ≥15 or a positive response for suicidal thoughts (Q9 of the PHQ-9 - any response other than not at all).\n* Any medication or condition that, in the opinion of the medical investigator, could interfere with the study outcomes or put the subject at risk by participating in the study.\n* Blood or plasma donation during the past 2 months.","45 Years",{"count":216,"type":23},100,[26],"Short sleep duration confers high cardiovascular and metabolic risk, but lifestyle factors and molecular mechanisms that contribute to increased blood pressure and poor glucose control during short sleep are not completely understood. Habitual short sleepers are constantly eating, the proposed studies will evaluate if this behavior contributes to heightened cardiovascular and metabolic risk. The study will evaluate if restricted eating duration (8 hours\u002Fday) could improve cardiovascular and metabolic health in habitual short sleepers.",[29],[221,222,223,224,225],"eating duration","short sleep duration","time-restricted eating","blood pressure","insulin resistance","2026-02-06",{"date":228,"type":40},"2026-02-10",{"date":230,"type":40},"2023-12-05",{"date":232,"type":23},"2028-06-30",{"name":234,"class":47},"Pennington Biomedical Research Center",{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":24,"phases":246,"briefSummary":247,"conditions":248,"keywords":257,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":48},"100618258","nighttime-synchrony-of-your-nutrition-and-circadian-health-100618258","NCT07329283","Nighttime Synchrony of Your Nutrition and Circadian Health","Nighttime Synchrony of Your Nutrition and Circadian Health: The N-Sync Study","N-Sync","Inclusion Criteria:\n\n1. Age: 18-35 years old; equal numbers of men and women\n2. Body Mass Index (BMI): 18.5-24.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) 7-9 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or apnea hypopnea index (AHI) ≥5\n2. Evidence of significant organ system dysfunction or disease (e.g., heart disease, diabetes)\n3. Fasting plasma glucose ≥100 mg\u002FdL\n4. Major psychiatric illness (e.g., major depressive disorder)\n5. Cancer that has been in remission less than 5 years\n6. History of shift-work in prior year\n7. Weight change \\>5% of body weight over prior six months\n8. Currently following a weight-loss program\n9. Menopause\n10. Pregnant\u002Fnursing\n11. Greater than 5-day variation in menstrual cycle length month-to-month\n12. Currently smoking\n13. Alcohol intake \\>14 drinks\u002Fweek or \\>3 drinks\u002Fday.\n14. Use of prescription medications (except oral contraceptives) within one month prior to or during in-lab visits.\n15. Consumption of illegal drugs or \\>500mg per day of caffeine.","35 Years",{"count":245,"type":23},120,[26],"Sleep is an important factor for overall health. This study will see how different light exposure patterns and food intake impact a person's metabolism (how the body breaks down food) when sleeping is reduced.\n\nParticipants will attend 6 to 8 in-person visits to the study clinic, including three overnight stays. People will complete surveys and medical tests. The study will last about 4 to 6 months.",[150,249,250,251,252,253,29,254,69,255,256],"Metabolism Changes","Circadian Rhythm","Lifestyle Factors","Sleep Hygiene","Sleep Hygiene, Inadequate","Insufficient Sleep","Circadian Dysregulation","Light Exposure",[150,256,258,250,259,251,252],"Metabolism","Food Intake","2026-01-20",{"date":262,"type":40},"2026-01-22",{"date":264,"type":40},"2025-12-19",{"date":266,"type":23},"2031-05-31",{"name":268,"class":47},"University of Utah",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":24,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":290,"locationsCount":48},"100599454","effects-of-non-invasive-superficial-craniocervical-lymphatic-drainage-nscld-on-memory-and-cognitive-function-in-adults-with-sleep-deprivation-a-proof-of-concept-study-100599454","NCT07084701","Effects of Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD) on Memory and Cognitive Function in Adults With Sleep Deprivation: A Proof-of-Concept Study","NSCLD","Inclusion Criteria:\n\n* College student ≥18 years, all of whom have passed a standardized entrance examination;\n* No failed exams during the course of study;\n* Sleep deprivation;\n* In good health, with no mental or psychological disorders;\n* No recent use of medications that may affect memory and cognition;\n* Voluntary participation and able to undergo cognitive function and memory testing;\n* Informed consent provided\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Presence of acute or chronic medical conditions (e.g., severe hypertension, diabetes, cardiovascular disease) that could confound the results.\n* History of craniocervical trauma or surgery.\n* Current use of sedative or anxiolytic medications that could influence sleep or cognitive function.\n* Participants who are unable to follow the procedures or complete the assessments",{"count":121,"type":23},[26],"This Effects of Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD) on Memory and Cognitive Function in Adults with Sleep deprivation: A Proof-of-Concept Study aims to investigate the effects of Non-Invasive Superficial Craniocervical Lymphatic Drainage (NSCLD) on memory and cognitive function in adults experiencing sleep deprivation(SD). Given the known impact of SD on cognitive performance, this study seeks to explore whether NSCLD, as a non-invasive intervention, can mitigate the cognitive impairments associated with SD.",[29],[29,281,282,283,274],"Non-Invasive Superficial Craniocervical Lymphatic Drainage","Memory","Cognitive Function","2026-01-11",{"date":286,"type":40},"2026-01-13",{"date":288,"type":40},"2025-09-15",{"date":136,"type":23},{"name":291,"class":47},"Tao Liu",{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":17,"sex":18,"minAge":299,"maxAge":300,"enrollmentInfo":301,"targetDuration":4,"studyType":24,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":4},"100615506","neurobehavioral-changes-following-spaceflight-stressors-100615506","NCT07293494","Neurobehavioral Changes Following Spaceflight Stressors","NeuroSTAR","Inclusion Criteria:\n\n* Age between 25-60 years.\n* Free of psychological, psychiatric or physical conditions that preclude participation.\n* BMI between 18.5 and 35.\n* Self-reported regular sleep schedule; able to maintain their sleep schedule during the course of the study.\n* Self-reported sleep duration of 6-8.5 h per night (verified by daily logs).\n* Ability to read\u002Fwrite English.\n* Able to stand unassisted for up to 10 minutes at a time and able to lift arms above head.\n\nExclusion Criteria:\n\n* Alcohol or drug abuse in the past year based upon history and urine toxicology screen.\n* Potential alcohol abuse or heavy drinking in the past year, based on self-report (AUDIT-C Q2 score above 1 or Q3 score above 2).\n* Alcohol-naive based on self-report (AUDIT-C Q1 score of 0).\n* Allergies, conditions or circumstances that preclude alcohol consumption, including use of medication or supplements (prescription or over the counter) that could interfere with study participation or make it hazardous for a subject to partake (e.g., anticholinergics; antipsychotics; lithium; psychotropic drugs not otherwise specified), or for which alcohol consumption should be limited or avoided (e.g. items identified on NIAAA's 'Harmful Interactions' list).\n* Cultural or personal beliefs that preclude alcohol consumption.\n* Body Mass Index ≤18.5 or ≥ 35.\n* Current smoker\u002Ftobacco user or using nicotine replacement therapy. Those that have been nicotine-free for ≥ 30 days may be included.\n* Excessive caffeine consumption (\\> 650mg\u002Fday combining all caffeinated drinks regularly consumed during the day).\n* Acute, chronic, or debilitating medical conditions, major Axis I psychiatric illness based on history, physical exam, blood and urine chemistries; or self-reported history of neurological, psychiatric, or other medical condition that precludes participation, such as nervous system disorders, dementia, chronic migraines, or epilepsy; panic, bipolar or schizoaffective disorder; sleep disorders including insomnia, narcolepsy and obstructive sleep apnea; liver, kidney or heart disease, hypertension; infectious diseases; diabetes; or any other conditions for which medical monitoring is advised and which may require medications and\u002For lifestyles that preclude alcohol consumption and\u002For sleep disruption.\n* Current depression as determined on the Beck Depression Inventory (Beck, 1996), by either a total score of 19 or higher or a response greater than 0 on Q9 (suicidality).\n* Cardiovascular, gastrointestinal, or musculoskeletal problems, or other major conditions such as organ failure, cancer or patients requiring oxygen.\n* Prior history or diagnosis of any sleep disorder including Obstructive Sleep Apnea (AHI ≥15 events\u002Fhour) - from ambulatory or in lab polysomnography; Restless legs syndrome or periodic limb movement disorder; Insomnia; Parasomnia; High Risk of OSA based on STOP-BANG Questionnaire (\"yes\" on at least 4 of 8 questions); High Risk of Restless Legs Syndrome (RLS) based on Cambridge-Hopkins Screening questionnaire; High Risk of Insomnia based on Insomnia Severity Index (score of 22 or higher).\n* Current use or use within the past month of a prescription or over-the-counter sleep medication or stimulant (based on self-report or review with a study clinician).\n* History of potential MRI contraindications, including: tinnitus; sensorineural hearing loss \\> 30 dB; pace maker or internal defibrillator; metallic implants (e.g. orthopedic plates after bone fractures, joint replacements, surgical staples or clips, artificial heart valves, stents, cava filters); metallic splinters (e.g. after an accident or due to war injury); non-removable dental brace; Tattoo (some tattoo inks contain metallic particles); permanent make-up; non-MRI compatible intrauterine contraceptive device; cochlear implant (implanted hearing device); medication pump; acupuncture needle; other foreign bodies\u002Fobjects which are non-removable; pregnancy (or its possibility); previous brain and\u002For heart surgery.\n* History of severe motion sickness, based on self-report or driving simulator response.\n* Pregnant or currently breast feeding. People that menstruate will have a pregnancy test performed via urine sample during screening, as those that are currently pregnant are unable to participate in the study.\n* Individuals who self-report severe contact dermatitis or allergy to bandages, silicone, nickel or silver.\n* Currently working night, swing, split or rotating shift.\n* Planned travel across more than one time zone within 7 days of the scheduled study start date.\n* Habitual daytime napping.","25 Years","60 Years",{"count":302,"type":23},56,[26],"This study aims to investigate the impairing effects of known central nervous system (CNS) stressors in a controlled environment in order to predict and mitigate analogous risks in spaceflight. Up to 56 healthy individuals aged 25-60 will spend approx. 110 hours in a laboratory, where they will be exposed to 27 hours of sleep deprivation and will consume alcohol to reach a BAC of 0.08 on a separate day. They will perform cognitive and sensorimotor tasks and undergo MRIs and blood draws.",[306,307,29,308],"Stressor, Individual","Alcohol Impairment","Impairment, Cognitive",{"date":310,"type":40},"2025-12-29",{"date":312,"type":23},"2026-06",{"date":314,"type":23},"2029-12",{"name":316,"class":47},"University of Pennsylvania",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":17,"sex":18,"minAge":325,"maxAge":214,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":332,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":348,"locationsCount":48},"100615605","circadian-rhythms-and-time-perception-in-healthy-adults-during-constant-wakefulness-100615605","NCT07294781","Circadian Rhythms and Time Perception in Healthy Adults During Constant Wakefulness","CircaTime: Effects of Circadian Rhythms on Time Perception During a 36-Hour Constant Routine in Healthy Adults","CircaTime","Inclusion Criteria:\n\n* Age 23 to 45 years.\n* Able and willing to provide written informed consent.\n* Fluent in Danish and able to understand study procedures and instructions.\n* Generally healthy, as assessed by medical history, screening questionnaires, and basic clinical measures (e.g., blood pressure, heart rate).\n* Self-reported regular sleep-wake schedule for at least 4 weeks prior to the laboratory visit (typically 6.5-9 hours of sleep per night, with usual sleep period between approximately 22:00-01:00 and 06:00-09:00).\n* Body mass index (BMI) within a non-extreme range (for example, approximately 18.5-30 kg\u002Fm²), if required by the study physician.\n* No regular night work or rotating shift work during the 3 months before participation.\n* No travel across more than 2 time zones in the 2 months before the constant-routine session.\n* Willing to abstain from caffeine, nicotine, alcohol, and recreational drugs for the specified washout periods before and during the 36-hour constant-routine session.\n* For participants who can become pregnant: negative pregnancy test at screening\u002Farrival and agreement to use reliable contraception for the duration of participation.\n\nExclusion Criteria:\n\n* Any known or suspected major sleep disorder (e.g., insomnia disorder, obstructive sleep apnoea, restless legs syndrome, narcolepsy), based on self-report or prior diagnosis.\n* Current or past major psychiatric or neurological disorders (e.g., major depressive disorder, bipolar disorder, psychotic disorders, epilepsy), unless considered mild and stable and explicitly approved by the study physician.\n* Chronic medical conditions that could be worsened by prolonged wakefulness or that might confound outcome measures, such as significant cardiovascular disease, uncontrolled hypertension, diabetes mellitus, severe respiratory disease, or other serious systemic illness.\n* Regular use of medications or supplements that may affect sleep, circadian rhythms, melatonin secretion, alertness, or mood (e.g., hypnotics, sedative-hypnotics, melatonin, stimulants, certain antidepressants or beta-blockers), unless a safe washout is possible and approved by the study physician.\n* High habitual caffeine intake (for example, \\>400 mg\u002Fday) or nicotine dependence if the participant is unable or unwilling to abstain for the required washout periods.\n* Current harmful alcohol use or substance use disorder, or frequent use of recreational drugs.\n* Pregnancy or breastfeeding.\n* Previous severe adverse reaction to sleep deprivation, extended wakefulness, or similar laboratory protocols.\n* Claustrophobia or inability to tolerate prolonged stays in a controlled laboratory environment.\n* Any condition or circumstance that, in the judgement of the investigators, would make participation unsafe, interfere with the 36-hour wakefulness protocol, or compromise data quality (e.g., inability to remain awake despite support, strong fear of needles or saliva sampling, or inability to comply with study restrictions).","23 Years",{"count":121,"type":23},[26],"This study examines how the internal body clock (circadian rhythms) influences the way healthy adults experience time, think, and feel when they stay awake for an extended period. Participants will spend about 36 hours in a controlled sleep laboratory while remaining awake the entire time. Light, posture, food intake, and activity are kept as constant as possible (a \"constant routine\") so that changes over time mainly reflect the body's internal clock and increasing sleepiness, rather than changes in the environment. Every two hours, participants complete a brief test battery that includes ratings of sleepiness and mood, a reaction-time task, and short tasks that assess how fast or slow time seems to pass, how accurately they can estimate time intervals, how they respond to simple decisions, and how they judge colours. Saliva samples are collected repeatedly to measure melatonin, a hormone that indicates circadian phase. By comparing changes in behaviour, perception, and melatonin levels across the 36-hour wake period, the study aims to identify when during the circadian cycle people are most vulnerable to distortions in time perception and reduced alertness. The findings may help improve scheduling of shift work and other activities that require sustained wakefulness.",[29,250,330,331],"Healthy Volunteers","Time Perception",[333,334,335,336,337,338,339,340,341],"Circadian rhythms","Constant routine","Extended wakefulness","Sleep loss","Time perception","Subjective time","Psychomotor vigilance task","Dim light melatonin onset","Healthy adults",{"date":343,"type":40},"2025-12-22",{"date":345,"type":40},"2025-12-05",{"date":347,"type":23},"2027-12-30",{"name":349,"class":47},"University of Aarhus",{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":356,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":48},"100599535","effects-of-acute-sleep-deprivation-on-individuals-with-different-apoe-genotypes-100599535","NCT07085754","Effects of Acute Sleep Deprivation on Individuals With Different APOE Genotypes","Inclusion Criteria:\n\n* Age 18-40 years, gender not limited\n* Healthy (with no clinically significant abnormal findings in the physical examination report or self-reporting as healthy) and not on medications\n* Cognitively normal (Mini-Mental State Examination (MMSE) score \\> 28)\n* Sleep duration of 7-9 hours per night, good sleep quality (Pittsburgh Sleep Quality Index (PSQI) ≤ 5 points)\n* Written informed consent, voluntarily participate in this study, and be able to cooperate with the physician to complete the clinical study\n\nExclusion Criteria:\n\n* Presence of day-night sleep reversal\n* Shift work within the past 6 months\n* Travel across time zones or experience of jet lag within the past three weeks\n* Current smoking or nicotine use; alcohol consumption exceeding five standard units per week (one standard alcohol unit is defined as 10 mL \\[or 8 g\\] of pure alcohol)\n* Consumption of strong tea, coffee, or caffeine-containing foods and beverages within one week before study participation\n* Family history of early-onset dementia\n* Self-Rating Depression Scale (SDS) score ≥ 53, Self-Rating Anxiety Scale (SAS) score ≥ 50\n* Female participants who are currently pregnant or breastfeeding\n* Individuals who need to drive or operate vehicles or machinery during the study period",{"count":22,"type":23},[26],"This study aims to investigate the effects of 24-hour acute sleep deprivation on plasma Alzheimer's disease biomarkers and multi-omics in individuals with different APOE genotypes, to elucidate the potential role of acute sleep deprivation in AD risk.",[150,29],"2025-12-18",{"date":362,"type":40},"2025-12-24",{"date":364,"type":40},"2025-08-08",{"date":366,"type":23},"2026-12-31",{"name":368,"class":47},"Yuhui Qiu",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":17,"sex":18,"minAge":174,"maxAge":20,"enrollmentInfo":375,"targetDuration":4,"studyType":24,"phases":377,"briefSummary":378,"conditions":379,"keywords":382,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":48},"100578263","evaluation-of-sex-differences-in-glucose-metabolism-in-response-to-sleep-curtailment-100578263","NCT06809023","Evaluation of Sex Differences in Glucose Metabolism in Response to Sleep Curtailment","Inclusion Criteria:\n\n* Healthy adults with conventional sleep-wake timing\n* Non-smokers\n* Completion of medical, psychological, and sleep screening tests\n* Able to spend 5 consecutive days\u002Fnights in the laboratory on two separate occasions (total of 10 days\u002Fnights in the laboratory)\n* Women must have a recent history of regular menstrual cycles\n\nExclusion Criteria:\n\n* History of neurological or psychiatric disorder\n* History of sleep disorder or regular use of sleep-promoting medication\n* Current prescription, herbal, or over-the-counter medication use including hormonal birth control\n* Traveling across 2 or more time zones within past 3 months\n* Donating blood within past 8 weeks\n* Worked night or rotating shift work within past year\n* Hearing impairment, visual impairment\n* History of eye trauma or surgery\n* Drug or alcohol dependency",{"count":376,"type":23},32,[26],"The goal of this study is to learn whether insufficient sleep affects glucose metabolism differently in healthy men and women.",[29,380,381],"Sex Differences","Glucose Tolerance",[383,129,384,385],"glucose metabolism","sex differences","GLP-1","2025-12-09",{"date":388,"type":40},"2025-12-10",{"date":390,"type":23},"2026-04",{"date":392,"type":23},"2029-02",{"name":394,"class":47},"Brigham and Women's Hospital",{"id":396,"slug":397,"hasResults":12,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":4,"eligibilityCriteria":401,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":403,"phases":4,"briefSummary":404,"conditions":405,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":48},"100564987","immune-status-after-being-on-call-for-24-hrs-100564987","NCT06636318","Immune Status After Being on Call for 24 Hrs","Impact of a 24-hour Shift Call on the Immune Status of Surgery Residents","Inclusion Criteria:\n\n* Healthy subjects\n* Surgery residents in a 24-hour shift rotation\n* Gender of subjects: Males and females\n* Age of subjects: 18 years old and older\n* Racial and Ethnic Origin: Any race or ethnicity\n\nExclusion Criteria:\n\n* Unwilling\u002Funable to sign informed consent\n* Vulnerable Subjects\u002FSubject Capacity to provide consent",{"count":22,"type":23},"OBSERVATIONAL","Sleep deprivation is a prevalent problem in modern societies. Sleep deprivation can cause hormonal changes, such as an increase in cortisol, as well as inflammation. Animal studies have shown an increase in inflammatory cytokine production following sleep deprivation. Additionally, humans experiencing sleep deprivation may experience a decrease in natural killer cells and lymphocytes.\n\nPhysicians, particularly those in surgical specialties, are often subjected to sleep deprivation as part of their medical residency training. This study hypothesizes that after 24-hour shifts, there is an increase in inflammatory response and impairment of the immune response against unspecific activation. This proposal aims to provide insight into the impact of sleep deprivation on the immune system of surgery residents by characterizing the phenotype and function of immune cells, as well as their correlation with biometric data.",[29],"2025-12-02",{"date":386,"type":40},{"date":409,"type":40},"2024-10-17",{"date":411,"type":23},"2027-12",{"name":413,"class":47},"University of Chicago",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":420,"eligibilityCriteria":421,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":422,"enrollmentInfo":423,"targetDuration":4,"studyType":24,"phases":425,"briefSummary":426,"conditions":427,"keywords":429,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":112},"100484506","caffeine-optimization-versus-standard-caffeine-dosage-2b-2-100484506","NCT05588934","Caffeine Optimization Versus Standard Caffeine Dosage (2B-2)","A Head-to-Head Comparison of the 2B-Alert Caffeine Optimization Algorithm Versus Standard Caffeine Dosing on Performance During Sleep Deprivation (2B-2)","2B-2","Inclusion Criteria:\n\n* Age 18-39 years of age\n* Must demonstrate adequate comprehension of the protocol by achieving a score of at least 80% correct on a short multiple-choice quiz\n\nExclusion Criteria:\n\n* Self-reported habitual nightly sleep amounts outside the target range of approximately 6-9 hours (i.e., less than 6 hours per night or more than 9 hours per night, on average)\n* Self-reported nighttime bedtimes earlier than approximately 2100 hours on average during weeknights (Sunday through Thursday)\n* Self-reported morning wake-up times later than approximately 0900 on average during weekdays (Monday through Friday)\n* Self-reported habitual napping (\\> 3 times per week)\n* Self-reported symptoms suggestive of a sleep disorder (to include but not limited to sleep disordered breathing\u002Fsleep apnea, narcolepsy, idiopathic hypersomnia, restless leg syndrome, parasomnias, rapid eye movement (REM) behavior disorder, etc.)\n* History of a sleep disorder (to include all of the above)\n* Any use of prescription or over-the-counter sleep aids during the 6-month period prior to screening indicative of a potential sleep disorder as determined by the examining study physician\n* History of neurologic disorder (e.g., seizure disorder, amnesia for any reason, hydrocephalus, multiple sclerosis)\n* Self-reported caffeine use \\> 400 mg per day on average\n* Score of 14 or above on the Beck Depression Inventory (BDI)\n* Score of 41 or above on the Spielberger Trait Anxiety Inventory (STAI-T)\n* Score below 31 or above 69 on the Morningness-Eveningness Questionnaire\n* Self-reported regular nicotine use (\\> 1 cigarette or equivalent per week) within the last 1 year) or positive nicotine\u002Fcotinine result during screening visit\n* Self-reported heavy alcohol use (≥14 drinks per week or as determined by the examining study physician) or positive saliva alcohol result during screening visit\n* History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction)\n* Underlying acute or chronic pulmonary disease requiring daily inhaler use\n* Kidney disease or kidney abnormalities\n* Liver disease or liver abnormalities\n* Self-reported history of psychiatric disorder requiring hospitalization or use of psychiatric medication for any length of time\n* Self-reported use of products or drugs that cannot be safely discontinued during in-laboratory phases (determined on a case-by-case basis by the examining study physician)\n* Self-reported current use of other illicit drugs (to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana) or positive urine drug screen\n* (Females only) positive urine pregnancy result\n* (Females only) self-reported or suspected current breast-feeding or collecting breast milk\n* Resting blood pressure above 140\u002F90 or resting pulse \\> 110 beats per minute (if a physician performs a repeat measurement, \\~20 minutes after original measure, and it is within range, volunteer will not be excluded)\n* BMI ≥ 30 (Obese Class I or greater)\n* Clinically significant values (as determined by the reviewing study physician) for any hematology or chemistry parameter\n* Inability to read and sign consent\n* (Military only) failure to obtain required approved official leave to participate\n* Failure to cooperate with requirements of the study, e.g. failure to complete 80% of Smart-Psychomotor Vigilance Tests (PVTs) during Phase 1 (Days 2-13)","39 Years",{"count":424,"type":23},180,[26],"This clinical trial will be a comparison between personalized recommended caffeine dosing regimen versus the standard recommended caffeine dosing regimen for sustaining performance during sleep deprivation and minimizing side effects and subsequent sleep disruption. The questions this study aims to answer are: Whether the personalized caffeine recommendations improve vigilance, sleepiness, and cognition after total sleep deprivation, compared to standard recommendations; Whether the personalized caffeine recommendation better addresses the physical and emotional side effects of total sleep deprivation, compared to standard recommendations; And whether personalized caffeine recommendations aids in better recovery sleep after total sleep deprivation, compared to standard recommendations.\n\nParticipants will be asked to:\n\n1. Complete a 13-day at-home portion, wearing an actigraph watch to measure activity and sleep, and complete motor vigilance tests up to six times a day.\n2. Complete a 4-day in-lab portion, where participants will have to complete one night of baseline sleep, undergo 62-hours of total sleep deprivation, and then complete one night of recovery sleep.\n3. During the in-lab portion of the study, participants will be asked to complete more motor vigilance tests.\n\nResearchers will be comparing the personalized caffeine recommendation group against the standard caffeine recommendation to see if it is better at addressing each of the main questions.",[29,428],"Caffeine",[430,431],"SLEEP","CAFFEINE","2025-10-31",{"date":434,"type":40},"2025-11-04",{"date":436,"type":40},"2023-06-09",{"date":438,"type":23},"2026-03",{"name":83,"class":47},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":24,"phases":449,"briefSummary":450,"conditions":451,"keywords":457,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":48},"100607732","shift-hours-impact-on-fatigue-and-tracking-of-eye-dynamics-100607732","NCT07192380","Shift Hours' Impact on Fatigue and Tracking of Eye Dynamics","SHIFTED","Inclusion Criteria:\n\nAssociate radiologists at IMADIS Group\n\n* In their current position for at least one year\n* Working at one of the IMADIS Group on-call centers\n* Performing night shifts during the study period\n* Able to wear an actimeter watch during the study period (it may be removed during certain procedures, but must be put back on afterwards)\n* Having given their free and informed consent to participate in the study\n\nNon- inclusion criteria:\n\n* Leave during the study period\n* Pregnant women, women in labor, or breastfeeding women\n* Subjects wearing glasses or contact lenses\n\nExclusion Criteria:\n\n\\- Having slept more than 6 hours during the night shift",{"count":448,"type":23},40,[26],"The goal of this clinical trial is to learn how night shift-induced sleep debt affects oculomotor patterns, attentional state, and diagnostic performance in emergency radiologists.\n\nThe main questions it aims to answer are:\n\n* Does sleep debt from a night shift alter oculomotor parameters, as eyes movements (speed and amplitude), fixation duration, pupil size?\n* Does a night shift impact radiologists' diagnostic accuracy, attentional state, and perceived fatigue? Researchers will compare radiologists after a night shift (sleep-deprived) with the same radiologists after a night of rest (control) to see if fatigue-related changes affect both visual exploration strategies and diagnostic performance.\n\nParticipants will:\n\n* Perform a guided saccade task assessed by eye tracking (primary endpoint),\n* Read thoracic CT scans (with and without pulmonary embolism cases) to assess diagnostic performance and visual exploration patterns,\n* Undergo EEG recording to measure attentional state,\n* Complete self-report questionnaires on sleepiness and fatigue.",[29,452,453,454,455,456],"Sleepiness","Eye-Tracking Technology","Radiologists","Tomography","Electroencephalography",[458,459,460,461,184,462],"Night-Shift","Radiology","performance","Eye-tracking","Eye strain","2025-09-17",{"date":465,"type":40},"2025-09-25",{"date":288,"type":23},{"date":468,"type":23},"2026-05-15",{"name":470,"class":206},"IMADIS Technologies et Services",{"id":472,"slug":473,"hasResults":12,"nctId":474,"briefTitle":475,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":478,"enrollmentInfo":479,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":481,"conditions":482,"keywords":488,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":48},"100553901","the-peripheral-blood-multi-omics-study-on-sleep-loss-100553901","NCT06492109","The Peripheral Blood Multi-Omics Study on Sleep Loss","The Peripheral Blood Multi-Omics Study on the Association of Sleep Loss With Aging and Alzheimer's Disease","Inclusion Criteria:\n\n1. Signed informed consent form；\n2. Meet the inclusion criteria for each arms.\n\nExclusion Criteria:\n\n1. Failure to provide informed consent;\n2. Inability to follow study procedures due to issues such as language barriers or cognitive impairment;\n3. Regular use of medications that may alter the relationship between sleep and outcome variables (e.g., opioid medications, benzodiazepines, and Z drugs \\[non-benzodiazepine hypnotics\\]);\n4. History of alcohol abuse, substance abuse, consciousness disorders, cerebrovascular disease, head injury, epilepsy, encephalitis, or other neurological disorders;\n5. Diagnosis of schizophrenia, severe depression, anxiety disorders, or other severe psychiatric conditions;\n6. Presence of severe arrhythmias, myocardial infarction within the last 6 months, severe pulmonary dysfunction, renal or hepatic insufficiency, severe anemia, severe gastrointestinal diseases, tumors, or other severe medical conditions.","80 Years",{"count":22,"type":23},[26],"Sleep plays a role in cognitive processes such as memory processing, attention processing, and overall cognitive function. In recent years, the bidirectional relationship between sleep loss and aging, as well as related neurodegenerative diseases, has garnered widespread attention. Sleep disorders are a typical clinical manifestation of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease and are closely related to the progression of these diseases. However, current research has yet to fully elucidate the physiological responses to sleep loss across different ages and cognitive levels, as well as the association and molecular basis between sleep loss, aging, and neurodegenerative diseases. This study aims to comprehensively characterize the transcriptional and metabolic changes in peripheral blood under sleep loss in populations of different ages and cognitive levels using multi-omics approaches and to preliminarily explore the role of sleep loss in aging and AD.",[29,483,484,485,486,487],"Aging","Alzheimer Disease","Healthy Lifestyle","Cognitive Decline","Shift-work Disorder",[489,490,491,492,493],"sleep loss","multi-omics","Metabolome","aging","alzheimer's disease","2025-07-30",{"date":496,"type":40},"2025-07-31",{"date":498,"type":40},"2024-06-20",{"date":500,"type":23},"2025-12-31",{"name":502,"class":47},"First Affiliated Hospital of Zhejiang University",{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":478,"enrollmentInfo":510,"targetDuration":4,"studyType":403,"phases":4,"briefSummary":512,"conditions":513,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":522,"locationsCount":4},"100595437","impact-of-sleep-deprivation-on-malnutrition-in-icu-intensive-care-unit-patients-100595437","NCT07032441","Impact of Sleep Deprivation on Malnutrition in ICU (Intensive Care Unit) Patients","Association Between Sleep Deprivation and Malnutrition in Intensive Care Unit Patients: A Prospective Observational Cohort Study","Inclusion Criteria:\n\n* Adult ICU patients (≥18 years)\n* Expected length of stay ≥5 days\n* No severe liver or kidney failure (to avoid confounding in nutritional metabolism)\n\nExclusion Criteria:\n\n* Pre-existing malnutrition upon admission (e.g., BMI \\\u003C18.5 or weight loss \\>10% within 6 months)\n* Neuromuscular diseases affecting metabolic assessment",{"count":511,"type":23},150,"Study Design This study is a prospective cohort design conducted at Zhongshan Hospital affiliated with Fudan University. It will involve systematic assessments of sleep quality, nutritional status, and associated clinical outcomes in adult ICU patients over a defined observation period.\n\nSample Size: An estimated 150 adult patients (≥18 years) will be recruited from the ICU.\n\nAssessments 1. Sleep Quality Assessment:\n\n1. Polysomnography (PSG): Sleep quality and duration will be quantified using PSG, which records brain waves, blood oxygen levels, heart rate, and breathing, as well as eye and leg movements. This will provide a comprehensive picture of sleep architecture and disturbances.\n2. Sleep Quality Index: In addition to PSG data, the Pittsburgh Sleep Quality Index (PSQI) will be administered to assess subjective sleep quality, sleep latency, duration, habitual sleep efficiency, sleep disturbances, and daytime dysfunction.\n\n2\\. Nutritional Status Evaluation:\n\n1. Nutritional Risk Screening Tools: The Nutritional Risk Screening (NRS-2002) and the Malnutrition Universal Screening Tool (MUST) will be applied to assess nutritional risk and identify malnutrition.\n2. Biochemical Assessment: Blood samples will be collected to measure biochemical indicators such as serum albumin, transferrin, prealbumin, and other relevant markers of nutritional status.\n3. Anthropometric Measurements: Body mass index (BMI) and muscle mass assessments will be conducted using bioelectrical impedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA) to quantify body composition.\n\n3\\. Physiological Monitoring:\n\n1. Continuous monitoring of vital signs, including heart rate, blood pressure, and respiratory rate, will be performed.\n2. Assessment of immune function through laboratory tests, including white blood cell count and levels of inflammatory markers (C-reactive protein).\n\n4\\. Complications Tracking:\n\n1\\. Data on complications such as infections, delayed wound healing, and respiratory failure will be systematically recorded throughout the ICU stay.\n\nThis study aims to elucidate the complex interplay between sleep deprivation and malnutrition in ICU patients. By identifying key associations and influencing factors, we hope to inform targeted clinical interventions that can improve patient care, recovery, and quality of life. The findings will serve as a foundation for future research exploring the intricate relationships between sleep and nutritional status in critical care settings.",[514,29,515],"ICU Hospitalization","Malnutrition Severe","2025-06-18",{"date":518,"type":40},"2025-06-24",{"date":520,"type":23},"2025-08-01",{"date":366,"type":23},{"name":523,"class":47},"Shanghai Zhongshan Hospital",{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":422,"enrollmentInfo":531,"targetDuration":4,"studyType":24,"phases":532,"briefSummary":533,"conditions":534,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":542,"locationsCount":48},"100281593","transcranial-electrical-stimulation-tes-at-slow-oscillation-so-frequency-during-nrem-sleep-100281593","NCT02945501","Transcranial Electrical Stimulation (TES) at Slow Oscillation (SO) Frequency During NREM Sleep","Transcranial Electrical Stimulation at Slow Oscillation Frequency During NREM Sleep: An Assessment of Effects on the Restorative Properties of Sleep","Inclusion Criteria:\n\n* Healthy men and non-pregnant, non-lactating women 18 to 39 years of age (inclusive)\n* Must demonstrate adequate comprehension of the protocol, by achieving a score of at least 80% correct on a short multiple-choice quiz. Individuals who fail to achieve a passing score on the initial quiz will be given one opportunity to retest after a review of protocol information. Individuals who fail the comprehension assessment for the second time will be disqualified.\n\nExclusion Criteria:\n\n* Self-reported habitual nightly sleep amounts outside the target range of 6 - 9 hours (i.e., less than 6 hours per night or more than 9 hours per night, on average) (Post-consent Checklist)\n* Self-reported nighttime lights-out times earlier than 2100 hours on average during weeknights (Sunday through Thursday) or later than 2300. (Post-consent Checklist)\n* Self-reported morning wake-up times later than 0800 on average during weekdays (Monday through Friday) (Post-consent Checklist)\n* Self-reported habitual napping (\\> 1 time a week in conjunction with normal sleep habits) (Post-consent Checklist)\n* A rating of 6 or below on question 2 or 3 of the Nonrestorative Sleep Scale, indicating the subject experiences relatively non-refreshing sleep\n* An average time to sleep onset of greater than 20 minutes as indicated on the Post-consent Checklist\n* Self-reported caffeine use in excess of 400 mg (e.g., approximately 8 caffeinated sodas or 4 12-oz cups of coffee) per day on average (Post-consent Checklist; document provides exclusionary limits for various caffeinated products).\n* Score of lower than 31 or higher than 69 on the Morningness-Eveningness Questionnaire (MEQ form)\n* Score of 14 or above on the Beck Inventory Form (BDI form)\n* Score of 41 or above on the Self-Evaluation Questionnaire\n* History of cardiovascular disease (to include but not limited to arrhythmias, valvular heart disease, congestive heart failure, history of sudden cardiac death or myocardial infarction) (Medical History and Examination Form)\n* History of neurologic disorder (to include, but not limited to epilepsy or another seizure disorder, amnesia for any reason, hydrocephalus, MS, narcolepsy or other sleep disorders) (Medical History and Examination form; sleep items on Post-Consent Checklist)\n* Underlying pulmonary disease requiring daily inhaler use (Medical History and Examination form)\n* Kidney disease or kidney abnormalities (Medical History and Examination form, laboratory results)\n* Liver disease or liver abnormalities (Medical History and Examination form, laboratory results)\n* Self-reported history of psychiatric disorder requiring hospitalization or psychiatric product within the last 2 years or for more than 3 months at one time. (Medical History and Examination form)\n* Self-reported or suspected regular nicotine use or addiction, defined as more than 1 cigarette or equivalent per week, within the last 1 year (Medical History and Examination form)\n* Self-reported or suspected heavy alcohol use; minimum limit to define heavy alcohol use is 14 drinks per week or as determined by the examining appropriately licensed study investigator (Medical History and Examination form)\n* Self-reported or suspected use of products or drugs that cannot be safely discontinued during in-laboratory phases, to be determined on a case-by-case basis by the examining appropriately licensed study investigator (Medical History and Examination form)\n* Self-reported or suspected current use of other illicit drugs, to include but not limited to benzodiazepines, amphetamines, cocaine, marijuana (Medical History and Examination form)\n* Positive urine pregnancy result\n* Resting blood pressure above 140\u002F90 or resting pulse \\> 110 (Medical History and Examination form). Note that if a repeat measurement is within range then the volunteer will not be excluded.\n* BMI ≥ 30 (Obese Class I or greater) (Medical History and Examination form)\n* Clinically significant values (as determined by the appropriately licensed study investigator reviewing the study) for any hematology or chemistry parameter. The appropriately licensed study investigator reviewing the laboratory values may opt to repeat any clinically significant tests and include volunteers whose repeat test values are not clinically significant.\n* Positive urine nicotine\u002Fcotinine result during screening visit (NicCheck™ I test strip results)\n* Positive urine drug result during screening visit\n* Any use of sleep aids during the 1 year prior to screening\n* Inability to read and sign consent\n* Lack of access to a quiet, dark environment conducive to sleep from 2100 until 0700 during a seven night period at the beginning of the study\n* Participation in any ongoing clinical trials.\n* The preceding exclusionary criteria are known to alter sleep (e.g., epilepsy; some neurological disorders), substantially increase inter-subject variability, and\u002For the disease or condition puts the subject outside the range of what is considered healthy. The PI also maintains the prerogative to disqualify a volunteer if it is deemed that the volunteer's participation would be unsafe for the volunteer or staff or would be disruptive to study conduct or their inclusion could compromise data integrity.\n* Volunteers meeting the Beck cut-off (a score of at least 14) and who carry health insurance will be instructed to call their health insurance Mental Health \u002F Substance Abuse referral number.\n* Volunteers meeting the first cut-off (score of at least 14 who are not insured will be provided with a community mental health referral contact specific to their county of residence.\n* The review of the medical history with the volunteer and the physical examination itself will be performed by an appropriately licensed study investigator. Results of screening urine and blood tests will be reviewed by an appropriately licensed study investigator. The Post-consent Checklist will be administered by a trained research technician and reviewed by the study principal investigator or an appropriately licensed study investigator. If an appropriately licensed study investigator deems it medically advisable, the investigator will share abnormal results with the volunteer, who will be referred to his\u002Fher personal physician for follow-up.\n* A volunteer who has been cleared for participation may participate in a session if the first day of the session is within 90 days of the screening date. If the first day of the study session is 91 or more days since the volunteer has been screened, the volunteer must re-screen to ensure there has not been a change in eligibility status.",{"count":448,"type":23},[26],"The purpose of this study is to determine if the enhancement of electroencephalographic (EEG) slow-wave activity using transcranial electrical stimulation (TES) at Slow Oscillation (SO) frequency, during a restricted period of nocturnal sleep, enhances the restorative properties of that period of sleep and improves performance during a subsequent period of sleep deprivation.",[29,535],"Mental Competency","2025-06-10",{"date":538,"type":40},"2025-06-13",{"date":540,"type":40},"2016-10-27",{"date":411,"type":23},{"name":543,"class":544},"U.S. Army Medical Research and Development Command","FED",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":552,"enrollmentInfo":553,"targetDuration":4,"studyType":24,"phases":554,"briefSummary":556,"conditions":557,"keywords":590,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":48},"100565622","phase-1-evaluating-the-efficacy-and-safety-of-prosomnia-sleep-therapy-in-patients-with-sleep-deprivation-and-chronic-insomnia-100565622","NCT06644573","Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia","PSHW","By adhering to the following criteria, the study aims to select a population that can safely undergo the PROSOMNIA Sleep therapy and for whom the therapy is most likely to be beneficial, ensuring the reliability and validity of the study outcomes.\n\nINCLUSION CRITERIA:\n\n1. Age Range: 18-65 years of age Reason: This age range includes adults who are most likely to benefit from the PROSOMNIA Sleep therapy and who can provide informed consent. It also excludes children and older adults who may have different physiological responses or additional health risks.\n2. Diagnosed or Undiagnosed Chronic Insomnia:\n\n   Reason: Included subjects have a consistent pattern of sleep disturbances that PROSOMNIA Sleep Therapy aims to treat.\n3. Diagnosed or Undiagnosed Sleep Deprivation:\n\n   Reason: Includes individuals who are not getting enough sleep quantity, which is a key condition that the PROSOMNIA Sleep Therapy aims to address.\n4. Diagnosed or Undiagnosed REM Sleep Inconsistencies:\n\n   Reason: Includes individuals who are not getting enough sleep quality and those with specific REM sleep phase issues that the PROSOMNIA Sleep Therapy is designed to improve.\n5. Failure to Respond to Conventional Sleep Treatments:\n\n   Reason: Focuses on subjects who have not found relief from existing sleep therapies, ensuring that the study population represents those in need of alternative solutions.\n6. Ability to Provide Informed Consent:\n\nReason: Ensures that participants understand the study and agree to participate voluntarily.\n\nEXCLUSION CRITERIA:\n\n1. Severe Obesity (BMI \\> 40):\n\n   Reason: Severe obesity can increase the risk of complications with anesthesia and may affect sleep patterns in ways that could confound study results.\n2. Cardiovascular Conditions:\n\n   Reason: Patients with significant heart conditions are at higher risk for complications during anesthesia.\n3. Neurological Disorders:\n\n   Reason: These diagnosed conditions and medications such as epilepsy could interfere with sleep patterns and responses to sleep therapy.\n4. Other Health Conditions Contraindicating Anesthesia:\n\n   Reason: Includes any condition that would make the use of anesthesia unsafe.\n5. Greater than ASA II Status:\n\n   Reason: The American Society of Anesthesiologists (ASA) physical status classification system classifies patients based on their pre-anesthesia medical conditions. Excluding those above ASA II ensures that only patients with mild systemic disease are included, to minimize risks.\n6. Current Use of Prohibited Medications:\n\n   Reason: Medications that could interfere with the combined use of anesthesia including, but not limited to sedatives and hypnotics; such as benzodiazepines, Z-drugs and barbiturates.\n7. Pregnancy or Breastfeeding:\n\nReason: Ensures the safety of the fetus or infant, as the effects of the PROSOMNIA Sleep therapy on pregnancy or lactation are unknown.","65 Years",{"count":216,"type":23},[555],"PHASE1","This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture.\n\nObjectives: The primary goals of the trial are to determine:\n\n1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep.\n2. Whether PSTx increases the duration of REM and\u002For NREM sleep.\n3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency).\n\nParticipants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan\u002FPropofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep.\n\nParticipant Criteria:\n\nInclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation.\n\nExclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II.\n\nStudy Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy.\n\nParticipants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit.\n\nTherapy Methodology:\n\nPROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan\u002FPropofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function.\n\nOutcome Measures:\n\nPrimary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency.\n\nSecondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx.\n\nSignificance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments.\n\nStudy Process:\n\nRecruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy.\n\nTherapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan\u002FPropofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages.\n\nPost-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators.\n\nPotential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options.\n\nKey Concepts:\n\nHomeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.",[558,29,559,560,561,151,562,563,564,565,566,567,568,569,570,571,572,573,574,575,576,577,578,250,255,579,580,581,582,150,583,584,585,586,587,588,589],"Chronic Insomnia","REM Behavior Disorder","REM Sleep Behavior Disorder","REM Sleep Measurement","Insomnia Related to Specified Disorder","Insomnia Due to Other Mental Disorder","Insomnia Comorbid to Psychiatric Disorder","Insomnia Due to Anxiety and Fear","Insomnia Related to Another Mental Condition","Insomnia Disorders","Idiopathic Hypersomnia","Sleep Disorders, Circadian Rhythm","Post Trauma Nightmares","PTSD - Post Traumatic Stress Disorder","Sleep Quality","Anesthesia","Anxiety","Depression","Mental Health","Alzheimer Disease or Associated Disorder","Parkinsons","PTSD","Post-Traumatic","Post-Traumatic Stress Disorder Complex","Military Combat Stress Reaction","Military Activity","Veterans","Shift Work Sleep Disorder","Menopause Related Conditions","Pain","Cancer Pain","Athletes",[430,591,592,593,594,595,596,597,598,599,600,601,602,603,604,605,606,607,151,29,608,568,609,579,576,574,575],"PROSOMNIA Sleep","PROSOMNIA Sleep Therapy","PSTx","PROSOMNIA","Anesthesia Sleep","REM Sleep","REM Sleep Therapy","PROSOMNIA Sleep Health","PROSOMNIA Sleep Wellness","PROSOMNIA Sleep Treatment","Nyree","Nyree Penn","Propofol","Propofol Sleep","Diprivan","Diprivan Sleep","PROSOMNIA Sleep Health and Wellness","IH","Sleep Debt","2025-05-27",{"date":612,"type":40},"2025-05-28",{"date":614,"type":23},"2025-11-01",{"date":616,"type":23},"2026-05-01",{"name":602,"class":206},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":622,"acronym":623,"eligibilityCriteria":624,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":625,"targetDuration":4,"studyType":24,"phases":626,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":48},"100480111","monitoring-of-attention-according-to-fatigue-in-the-healthy-subject-100480111","NCT05531734","MONITORING OF ATTENTION ACCORDING TO FATIGUE IN THE HEALTHY SUBJECT","MOTIVATES","Inclusion Criteria:\n\n* Healthy volunteers.\n* Male, female.\n* Medical residents.\n* Aged between 24 and 34 years.\n* Doing emergency, intensive care or \"inside\" shifts.\n* Working in a health institution.\n* No history of epilepsy.\n* No background treatment that could have an impact on the EEG (electroencephalogram) data (type: benzodiazepines, anti-epileptics).\n* No significant change in background treatment during the study, if any.\n* Affiliation to the social security system.\n* Informed volunteer who has signed a consent form.\n\nExclusion Criteria:\n\n\\-",{"count":121,"type":23},[26],"To develop an easy-to-use measurement tool for monitoring fatigue and alertness, particularly in sleep-deprived subjects.",[629,29],"FATIGUE",[631,632,129,633,634],"Measurement tool","EEG data","attention","electroencephalogram","2025-04-25",{"date":637,"type":40},"2025-04-27",{"date":639,"type":40},"2023-03-22",{"date":641,"type":23},"2025-09",{"name":643,"class":47},"Assistance Publique - Hôpitaux de Paris",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":4,"eligibilityCriteria":649,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":650,"enrollmentInfo":651,"targetDuration":4,"studyType":24,"phases":653,"briefSummary":654,"conditions":655,"keywords":659,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":668,"completionDateStruct":670,"leadSponsor":672,"locationsCount":48},"100572729","the-dream-team-testing-implementation-of-a-sleep-intervention-for-perinatal-women-delivered-by-direct-care-workers-100572729","NCT06737055","The Dream Team: Testing Implementation of a Sleep Intervention for Perinatal Women Delivered by Direct Care Workers","Phase 1 Inclusion Criteria:\n\nTo qualify for Phase 1 enrollment, participants must be:\n\n* over 18 years of age;\n* working with expectant and new mothers in a community setting (i.e., outpatient clinic, social service agency, home visiting program, community center);\n* in a role where they would be expected to meet with the same client on at least 4 occasions during the perinatal period; in situations where a team-based approach is used to provide services and a client may not see the exact same person at each visit, team members will qualify if they all enroll in the study (e.g., two nurse midwives who provide coverage for each other may both enroll);\n* have access to a smart phone to view the training videos, complete the assessments, and access the free CBTi Coach app; speak and read English or Spanish;\n* express interest in providing their clients with additional tools to manage sleep disturbances in pregnancy and the postpartum period.\n\nPhase 1 Exclusion Criteria:\n\nThe investigators will exclude potential participants who:\n\n* already have certification or a specialty in perinatal sleep (e.g., therapists with formal training in CBTi, individuals with sleep coaching practices);\n* those who do not have longitudinal relationships with clients (e.g., intake workers).\n\nPhase 2 Inclusion Criteria:\n\nTo qualify, Phase 2 participants must be:\n\n* expectant parents OR new parents up to 1 year postpartum;\n* age 18 to 45 years old;\n* receiving community-based health, well-being, and or mental health services or treatment from individuals who participated in Phase 1;\n* speak and read English or Spanish;\n* have access to a smart phone to view the training videos and complete the assessments;\n* have clinically significant sleep difficulties defined as an Insomnia Severity Index score greater than 7.\n\nPhase 2 Exclusion Criteria:\n\nThe investigators will exclude potential participants whose infants will not be living in the home or who will have a nighttime caregiver.","99 Years",{"count":652,"type":23},55,[26],"Insufficient and disrupted sleep are rarely addressed in expectant and new mothers, despite evidence that disturbed sleep is a modifiable risk factor for negative health outcomes for mothers and their children. In this study the investigators will adapt, refine, and pilot test the implementation of a behavioral sleep intervention consisting of short videos designed to accompany a free behavioral sleep app. In Phase 1, the investigators will develop and refine the intervention with input from direct care workers who serve at-risk perinatal women. In Phase 2, direct care workers will deploy the training to expectant mothers with sleep concerns and the investigators will assess the reach, effectiveness, adoption, implementation, and maintenance of this scalable, efficient intervention to improve sleep.",[150,656,657,151,29,252,658],"Postpartum Depression","Pregnancy Related","Sleep Disturbance",[660,661,662,663,664],"Home visitors","sleep diaries","education","implementation","RE-AIM","2024-12-23",{"date":667,"type":40},"2024-12-27",{"date":669,"type":40},"2023-08-08",{"date":671,"type":23},"2025-06-30",{"name":673,"class":47},"Rhode Island Hospital",{"id":675,"slug":676,"hasResults":12,"nctId":677,"briefTitle":678,"officialTitle":679,"acronym":4,"eligibilityCriteria":680,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":214,"enrollmentInfo":681,"targetDuration":4,"studyType":24,"phases":683,"briefSummary":684,"conditions":685,"keywords":691,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":48},"100529981","effect-of-sleep-extension-on-ceramides-in-people-with-overweight-and-obesity-100529981","NCT06180837","Effect of Sleep Extension on Ceramides in People with Overweight and Obesity","Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 27.5-34.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)\n3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg\u002FdL or HbA1c ≥6.5%\n4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.\n5. Cancer that has been in remission less than 5 years\n6. Pregnant\u002Fnursing, experiencing menopause or post-menopausal\n7. Shift-work: current or history of within last year\n8. Weight change: \\>10% of body weight over prior six months\n9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n10. Currently smoking\n11. Alcohol intake\\>14 drinks per week or \\>3 drinks per day",{"count":682,"type":23},70,[26],"The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[251,686,687,688,252,689,150,29,690],"Overweight and Obesity","Insulin Sensitivity","Eating Habit","Type 2 Diabetes","Insufficient Sleep Syndrome",[692,693],"sleep","insulin sensitivity","2024-12-18",{"date":696,"type":40},"2024-12-20",{"date":698,"type":40},"2024-02-12",{"date":700,"type":23},"2028-01",{"name":268,"class":47},{"id":703,"slug":704,"hasResults":12,"nctId":705,"briefTitle":706,"officialTitle":707,"acronym":708,"eligibilityCriteria":709,"healthyVolunteers":17,"sex":710,"minAge":19,"maxAge":243,"enrollmentInfo":711,"targetDuration":4,"studyType":24,"phases":712,"briefSummary":713,"conditions":714,"keywords":719,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":721,"lastUpdatePostDateStruct":722,"startDateStruct":724,"completionDateStruct":726,"leadSponsor":727,"locationsCount":48},"100568593","the-effects-of-night-shift-work-on-health-across-the-menstrual-cycle-100568593","NCT06683248","The Effects of Night Shift Work on Health Across the Menstrual Cycle","The Effects of Night Shift Work on Health Across the Menstrual Cycle: a Pilot Study","MENSLEEP","Inclusion Criteria:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives\n* Chronic disease\n* Regular use of nicotine\n* Use of medication\n* Consumes excessive amounts of alcohol or coffee","FEMALE",{"count":22,"type":23},[26],"The study aims to investigate the effects of sleep deprivation on women's health across different phases of the menstrual cycle.",[29,715,716,258,717,718],"Menstrual Cycle","Brain Health","Microbiota","Immune System",[720],"Estrogen","2024-11-11",{"date":723,"type":40},"2024-11-14",{"date":725,"type":40},"2022-04-25",{"date":500,"type":23},{"name":728,"class":47},"Uppsala University",{"id":730,"slug":731,"hasResults":12,"nctId":732,"briefTitle":733,"officialTitle":734,"acronym":735,"eligibilityCriteria":736,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":737,"targetDuration":4,"studyType":24,"phases":738,"briefSummary":739,"conditions":740,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":743,"lastUpdatePostDateStruct":744,"startDateStruct":746,"completionDateStruct":748,"leadSponsor":750,"locationsCount":112},"100563779","digital-technology-for-sleep-and-homelessness-100563779","NCT06620601","Digital Technology for Sleep and Homelessness","Diagnosis and Treatment of Sleep Apnea in Shelter Residents","HNSLEEP","Inclusion Criteria:\n\n* Residing in a shelter at the time of recruitment\n* Age \\>18 years old\n\nExclusion Criteria:\n\n* Allergies to medical tape \\[for diagnosis study\\].\n* Requiring extensive dental treatment or periodontal disease with tooth mobility \\[for treatment study\\].",{"count":216,"type":23},[26],"In Canada, 35,000 people are experiencing homelessness on any night. Compared to the general population, people experiencing homelessness (PEH) sleep less and experience increased daytime fatigue. A common sleep disorder and treatable cause of morbidity and low quality of life is sleep apnea. High prevalence of chronic comorbid disorders of sleep apnea in PEH suggest high prevalence of sleep apnea, but the rate of sleep apnea treatment in PEH is very low. Also, in PEH, individual and systemic barriers lead to a high rate of underdiagnosed and untreated sleep apnea. Mortality is higher in PEH than the general population, and sleep apnea remains a potential silent cause of morbidity and low quality of life in PEH. Our goal is to diagnose and treat sleep apnea in people living in shelters and to examine the effect of patient-centered treatment on their quality of life.",[741,742,29,658],"Sleep Apnea","Sleep Disorder","2024-09-26",{"date":745,"type":40},"2024-10-01",{"date":747,"type":40},"2021-10-20",{"date":749,"type":23},"2025-10",{"name":751,"class":47},"University Health Network, Toronto"]